Formulation of Neulasta (pegfilgrastim)
- PMID: 17822802
- DOI: 10.1016/j.addr.2007.04.017
Formulation of Neulasta (pegfilgrastim)
Abstract
Neulasta (pegfilgrastim) is a PEGylated version of its parent molecule NEUPOGEN (Filgrastim). This work describes the formulation development for Neulasta (pegfilgrastim), and the analytical techniques used to monitor degradation during these studies. Stability was assessed as a function of pH, protein concentration, buffer type, tonicity modifiers and surfactant concentration under both accelerated conditions and quiescent long-term storage. The stability of Neulasta (pegfilgrastim) to agitation and successive freeze-thaw cycles was also assessed. Neulasta (pegfilgrastim), at a protein concentration of 10 mg/mL formulated in 10 mM acetate, pH 4.0 with 5% sorbitol and 0.004% polysorbate 20, is stable for two years stored at 2-8 degrees C.
Similar articles
-
Stability studies of anticancer agent bis(4-fluorobenzyl)trisulfide and synthesis of related substances.J Pharm Biomed Anal. 2008 Nov 4;48(3):664-71. doi: 10.1016/j.jpba.2008.06.013. Epub 2008 Jul 3. J Pharm Biomed Anal. 2008. PMID: 18678459
-
Formulation development and manufacturing of a gastrin/CCK-2 receptor targeting peptide as an intermediate drug product for a clinical imaging study.Eur J Pharm Sci. 2007 Jun;31(2):102-11. doi: 10.1016/j.ejps.2007.02.007. Epub 2007 Feb 23. Eur J Pharm Sci. 2007. PMID: 17387005
-
Formulation development and stability testing of oral morphine solution utilizing preformulation approach.J Pharm Pharm Sci. 2005 Aug 18;8(2):362-9. J Pharm Pharm Sci. 2005. PMID: 16124948
-
The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation.Crit Rev Ther Drug Carrier Syst. 1993;10(4):307-77. Crit Rev Ther Drug Carrier Syst. 1993. PMID: 8124728 Review.
-
Role of racemization in optically active drugs development.Chirality. 2007 Jun;19(6):453-63. doi: 10.1002/chir.20397. Chirality. 2007. PMID: 17393472 Review.
Cited by
-
Approved Nanomedicine against Diseases.Pharmaceutics. 2023 Feb 26;15(3):774. doi: 10.3390/pharmaceutics15030774. Pharmaceutics. 2023. PMID: 36986635 Free PMC article. Review.
-
Site-Specific PEGylation of Therapeutic Proteins.Int J Mol Sci. 2015 Oct 28;16(10):25831-64. doi: 10.3390/ijms161025831. Int J Mol Sci. 2015. PMID: 26516849 Free PMC article. Review.
-
Insights on Development Aspects of Polymeric Nanocarriers: The Translation from Bench to Clinic.Polymers (Basel). 2022 Aug 29;14(17):3545. doi: 10.3390/polym14173545. Polymers (Basel). 2022. PMID: 36080620 Free PMC article. Review.
-
Design of novel granulopoietic proteins by topological rescaffolding.PLoS Biol. 2020 Dec 22;18(12):e3000919. doi: 10.1371/journal.pbio.3000919. eCollection 2020 Dec. PLoS Biol. 2020. PMID: 33351791 Free PMC article.
-
New agents in HSC mobilization.Int J Hematol. 2017 Feb;105(2):141-152. doi: 10.1007/s12185-016-2156-2. Epub 2016 Nov 30. Int J Hematol. 2017. PMID: 27905003 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources